230 related articles for article (PubMed ID: 31969373)
1. A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.
Zeleznik OA; Eliassen AH; Kraft P; Poole EM; Rosner BA; Jeanfavre S; Deik AA; Bullock K; Hitchcock DS; Avila-Pacheco J; Clish CB; Tworoger SS
Cancer Res; 2020 Mar; 80(6):1357-1367. PubMed ID: 31969373
[TBL] [Abstract][Full Text] [Related]
2. Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study.
Zeleznik OA; Clish CB; Kraft P; Avila-Pacheco J; Eliassen AH; Tworoger SS
J Natl Cancer Inst; 2020 Jun; 112(6):628-636. PubMed ID: 31593240
[TBL] [Abstract][Full Text] [Related]
3. Plasma Metabolomics and Breast Cancer Risk over 20 Years of Follow-up among Postmenopausal Women in the Nurses' Health Study.
Brantley KD; Zeleznik OA; Rosner B; Tamimi RM; Avila-Pacheco J; Clish CB; Eliassen AH
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):839-850. PubMed ID: 35064065
[TBL] [Abstract][Full Text] [Related]
4. Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides.
Trabert B; Hathaway CA; Rice MS; Rimm EB; Sluss PM; Terry KL; Zeleznik OA; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Nov; 30(11):2044-2051. PubMed ID: 34404683
[TBL] [Abstract][Full Text] [Related]
5. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.
Peres LC; Townsend MK; Birmann BM; Conejo-Garcia JR; Kim Y; Kubzansky LD; Magpantay LI; Martinez-Maza O; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):710-718. PubMed ID: 33563649
[TBL] [Abstract][Full Text] [Related]
6. Prolactin and Risk of Epithelial Ovarian Cancer.
Hathaway CA; Rice MS; Townsend MK; Hankinson SE; Arslan AA; Buring JE; Hallmans G; Idahl A; Kubzansky LD; Lee IM; Lundin EA; Sluss PM; Zeleniuch-Jacquotte A; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1652-1659. PubMed ID: 34244157
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
8. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.
Peres LC; Mallen AR; Townsend MK; Poole EM; Trabert B; Allen NE; Arslan AA; Dossus L; Fortner RT; Gram IT; Hartge P; Idahl A; Kaaks R; Kvaskoff M; Magliocco AM; Merritt MA; Quirós JR; Tjonneland A; Trichopoulou A; Tumino R; van Gils CH; Visvanathan K; Wentzensen N; Zeleniuch-Jacquotte A; Tworoger SS
Cancer Res; 2019 Oct; 79(20):5442-5451. PubMed ID: 31462430
[TBL] [Abstract][Full Text] [Related]
9. Genetically predicted circulating protein biomarkers and ovarian cancer risk.
Considine DPC; Jia G; Shu X; Schildkraut JM; Pharoah PDP; Zheng W; Kar SP;
Gynecol Oncol; 2021 Feb; 160(2):506-513. PubMed ID: 33246661
[TBL] [Abstract][Full Text] [Related]
10. The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Hemmingsen CH; Kjaer SK; Bennetsen AKK; Dehlendorff C; Baandrup L
Gynecol Oncol; 2021 Aug; 162(2):469-474. PubMed ID: 34016454
[TBL] [Abstract][Full Text] [Related]
11. Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Hada M; Edin ML; Hartge P; Lih FB; Wentzensen N; Zeldin DC; Trabert B
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):189-197. PubMed ID: 30262599
[TBL] [Abstract][Full Text] [Related]
12. Risk of epithelial ovarian cancer among women with benign ovarian tumors: a follow-up study.
Guleria S; Jensen A; Toender A; Kjaer SK
Cancer Causes Control; 2020 Jan; 31(1):25-31. PubMed ID: 31673820
[TBL] [Abstract][Full Text] [Related]
13. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition.
Ose J; Fortner RT; Rinaldi S; Schock H; Overvad K; Tjonneland A; Hansen L; Dossus L; Fournier A; Baglietto L; Romieu I; Kuhn E; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Masala G; Sieri S; Tumino R; Sacerdote C; Mattiello A; Ramon Quiros J; Obón-Santacana M; Larrañaga N; Chirlaque MD; Sánchez MJ; Barricarte A; Peeters PH; Bueno-de-Mesquita HB; Onland-Moret NC; Brändstedt J; Lundin E; Idahl A; Weiderpass E; Gram IT; Lund E; Kaw KT; Travis RC; Merritt MA; Gunther MJ; Riboli E; Kaaks R
Int J Cancer; 2015 Jan; 136(2):399-410. PubMed ID: 24890047
[TBL] [Abstract][Full Text] [Related]
14. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk.
McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Kaaks R; Rinaldi S; Helzlsouer KJ
Int J Cancer; 2009 Aug; 125(3):674-9. PubMed ID: 19444906
[TBL] [Abstract][Full Text] [Related]
15. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.
Poole EM; Merritt MA; Jordan SJ; Yang HP; Hankinson SE; Park Y; Rosner B; Webb PM; Cramer DW; Wentzensen N; Terry KL; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):429-37. PubMed ID: 23307531
[TBL] [Abstract][Full Text] [Related]
16. Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.
Barnard ME; Poole EM; Curhan GC; Eliassen AH; Rosner BA; Terry KL; Tworoger SS
JAMA Oncol; 2018 Dec; 4(12):1675-1682. PubMed ID: 30286239
[TBL] [Abstract][Full Text] [Related]
17. Circulating inflammation markers and risk of epithelial ovarian cancer.
Clendenen TV; Lundin E; Zeleniuch-Jacquotte A; Koenig KL; Berrino F; Lukanova A; Lokshin AE; Idahl A; Ohlson N; Hallmans G; Krogh V; Sieri S; Muti P; Marrangoni A; Nolen BM; Liu M; Shore RE; Arslan AA
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):799-810. PubMed ID: 21467242
[TBL] [Abstract][Full Text] [Related]
18. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
19. Posttraumatic Stress Disorder Is Associated with Increased Risk of Ovarian Cancer: A Prospective and Retrospective Longitudinal Cohort Study.
Roberts AL; Huang T; Koenen KC; Kim Y; Kubzansky LD; Tworoger SS
Cancer Res; 2019 Oct; 79(19):5113-5120. PubMed ID: 31488422
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of serum metabolites and colorectal cancer risk.
Cross AJ; Moore SC; Boca S; Huang WY; Xiong X; Stolzenberg-Solomon R; Sinha R; Sampson JN
Cancer; 2014 Oct; 120(19):3049-57. PubMed ID: 24894841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
